Yuxiang Ren is a PhD student at Monash University, working in the areas of mRNA therapeutics, nanomedicine, and pharmacokinetics. He received his Bachelor’s degree from Zhejiang University in 2020 and completed his Master’s training at ETH Zurich in 2023, where he developed a solid foundation in drug delivery systems and translational pharmaceutical research. His current research focuses on lipid nanoparticle (LNP)–based mRNA delivery, metabolic disease, and the in vivo pharmacokinetic and biodistribution profiling of nucleic acid therapeutics. He is particularly interested in how formulation parameters influence therapeutic performance and safety. Outside of research, he enjoys traveling, scuba diving, badminton, and photography.

Professor Lie-Fen Shyur is a Distinguished Research Fellow in the Agricultural Biotechnology Research Center, Academia Sinica, and also holds adjunct or joint professorships at thirteen academic/research institutions in Taiwan. The ultimate goal of Dr. Shyur’s lab research is to develop plant-based agents for human and animal health care. Her research achievements include publication of >120 research articles in high-profile and reputed journals, such as Pharmacological Research, Pharmacology and Therapeutics, Cancer Research, International Journal of Cancer, Molecular and Cancer Therapeutics, Molecular Oncology, Current Opinion in Chemical Biology, Journal of Medicinal Chemistry, etc. Dr. Shyur has obtained >35 international patents and several national and prestigious awards. In 2017, Shyur lab in collaboration with Development Center for Biotechnology (DCB), Taiwan received U.S. Food & Drug Administration (FDA) approval for Zhaohe Cao-based botanical drug as an Investigational New Drug (IND) for cancer therapy.

Dr. Qianqian Guo is an Assistant Research Fellow at Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. She earned her Ph.D. in Biomedical Engineering from Shanghai Jiao Tong University in 2023. Her research focuses on personalized cancer vaccines by modulating dendritic cell antigen presentation. She has published six SCI papers as first/co-first author in journals including Biomaterials, Hepatology, ACS AMI, and Exploration. Dr. Qianqian Guo is the principal investigator of Young Scientists Fund of the National Natural Science Foundation of China. She holds eight Chinese patent applications, with one granted as first inventor. She serves as a youth editorial board member for Life Medicine and Nano TransMed. She received the First Prize at the 2023 Annual Symposium of the Shanghai Pharmaceutical Association and was named an Outstanding Graduate of Shanghai Jiao Tong University.

Xin Luan is currently a Professor at Shanghai University of Traditional Chinese Medicine. He earned his Bachelor’s degree in Pharmaceutics from China Pharmaceutical University in 2011 and obtained his Ph.D. in Pharmacology from Shanghai Jiao Tong University in 2016. He subsequently completed a postdoctoral fellowship at the University of Michigan in 2018. His research primarily focuses on the discovery and antitumor mechanism of bioactive natural products toward new drug leads.

Dr. Lanyi Wei is a clinical pharmacy researcher at the Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai, China. Her research focused on clinical pharmacology and the antitumor pharmacology of traditional Chinese medicine. She has published three first-author papers in Q1 SCI journals and one first-author paper in a Q2 SCI journal.

Jiranan Chotitumnavee is a lecturer in the Department of Pharmacology, Faculty of Dentistry, Mahidol University, Thailand. Her research focuses on epigenetic regulation and targeted protein degradation, particularly PROTAC-based strategy, to elucidate how HDAC8-targeting PROTAC influence cancer cell survival and cellular functions.